Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: Placebo, Canagliflozin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Abraxane, Carboplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Nail Growth Cessation, Intraocular Pressure
Interventions: Bimatoprost 0.01%, Placebo: saline; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Neutropenia, Sarcoma
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 35 more

Conditions: Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions: HGF plasmid, Placebo; Genetic
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Conditions: Alzheimer Disease
Interventions: Human Nerve Growth Factor; Genetic
Lead sponsor: The Shiley Family Trust; Other
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions: LFG316, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more

Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Interventions: EMB-01; Drug
Lead sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan • Canton, Ohio

Conditions: Skin Toxicities
Interventions: Questionnaire; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Growth
Interventions: Marketed cow's milk-based infant formula, Cow's milk-based infant formula with added nutrients; Other
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 10 Days to 14 Days
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Dothan, Alabama • Fayetteville, Arkansas + 14 more

Conditions: Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions: Osimertinib 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Santa Rosa, California • Las Vegas, Nevada • White Plains, New York

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Conditions: Solid Tumors
Interventions: ASP5878; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 20 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Orange, California • New York, New York • Cleveland, Ohio + 3 more

Conditions: Endometrial Carcinoma
Interventions: Arsenic trioxide; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tuberous Sclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Choroidal Neovascularization
Interventions: Imatinib Mesylate /Ranibizumab; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 51 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Cochlear Implant
Interventions: cochlear implant revision surgery; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: PolG, Primary Mitochondrial Myopathy
Interventions: Not listed
Lead sponsor: The POLG Foundation; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: San Diego, California • Aurora, Colorado • New York, New York + 4 more

Conditions: Myotonic Dystrophy
Interventions: SomatoKine/IPLEX; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Treatment Induced Hypertension
Interventions: Minoxidil, Hydralazine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Growth Disorder, Growth Hormone Deficiency in Children
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 4 Years to 13 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more

Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Interventions: HER3-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
U.S. locations: 21
States / cities: Springdale, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more

Search by objective public record fields.

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

Gene Therapy for Alzheimer's Disease Clinical Trial

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study

Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Trisenox® in Women With Metastatic Endometrial Cancer

Study of Skin Tumors in Tuberous Sclerosis

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Tissue Growth Characterization for Cochlear Implant Users

Prospective Natural History Study of POLG Disease

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

Medical Access Program for Patritumab Deruxtecan